The data suggest a limited role of AR IHC for the distinction of tumors and a strong prognostic role in breast cancer and clear cell RCC and highlight numerous tumor entities that could benefit from androgen-targeting cancer drugs. This evidence concerns the gene AR and breast carcinoma.